Limited Competition: Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PAR-24-105
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Small Businesses
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Notice of Funding Opportunity invites applications to continue support of the Mutant Mouse Resource and Research Centers consortium through September 30, 2027. The consortium, comprised of four regional MMRRCs and an Informatics Coordination and Service Center, acquires, characterizes, preserves, and distributes mutant mouse strains to support biomedical research. Each MMRRC must also conduct a small high-risk, high-return research pilot project complementing the consortium's goals. The National Institutes of Health will evaluate applications submitted through grants.gov by September 1, 2024 under the Research Infrastructure Programs grant program.
Awards will be issued as cooperative agreements to eligible institutions. Each MMRRC in addition to performing major resource activities is required to develop the aforementioned pilot research project. It is expected the consortium will facilitate research through identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains and related biomaterials to qualified investigators.
Synopsis
This Notice of Funding Opportunity (NOFO) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium.
Files
| File | Type | Posted |
|---|---|---|
| PAR-24-105-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity